Vogenx Inc Common Stock (VOGX) - Total Liabilities
Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) has total liabilities worth $2.30 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is Vogenx Inc Common Stock's working capital to evaluate short-term liquidity relative to the company's equity base.
Vogenx Inc Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Vogenx Inc Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Vogenx Inc Common Stock assets under control.
Vogenx Inc Common Stock Competitors by Total Liabilities
The table below lists competitors of Vogenx Inc Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oxford Industries Inc
NYSE:OXM
|
USA | $814.46 Million |
|
Pitti Engineering Limited
NSE:PITTIENG
|
India | Rs11.51 Billion |
|
Linc AB
ST:LINC
|
Sweden | Skr7.75 Million |
|
Aduro Clean Technologies Inc. Common Stock
NASDAQ:ADUR
|
USA | $8.46 Million |
|
Beijing Succeeder Technology Inc
SHG:688338
|
China | CN¥69.11 Million |
|
Joyware Electronics Co Ltd
SHE:300270
|
China | CN¥231.70 Million |
|
Jay Mart Public Company Limited
BK:JMART
|
Thailand | ฿23.37 Billion |
|
BlackRock Municipal Income Closed Fund
NYSE:BFK
|
USA | $337.82 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Vogenx Inc Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See VOGX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vogenx Inc Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual total liabilities of Vogenx Inc Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.60 Million | +247.30% |
| 2024-12-31 | $460.81K | -- |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more